Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML

LEUKEMIA

NATURE PUBLISHING GROUP

1. NCI NIH HHS [R01 CA130876, R37 CA036167, R01 CA036167, P01 CA066996, CA36167, CA66996] Funding Source: Medline
2. NIDDK NIH HHS [P01 DK050654, DK50654] Funding Source: Medline